- Home
- RGA vs ARWR Comparison
RGA vs ARWR Comparison
Compare RGA & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGA | ARWR |
|---|---|---|
| Founded | 1973 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0B | 12.4B |
| IPO Year | 1996 | 2009 |
Fundamental Metrics
Financial Performance| Metric | RGA | ARWR |
|---|---|---|
| Price | $245.56 | $67.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $241.50 | $83.40 |
| AVG Volume (30 Days) | 229.1K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | 64.86 | ★ 99.80 |
| EPS | ★ 11.99 | N/A |
| Revenue | ★ $23,698,000,000.00 | $16,142,321.00 |
| Revenue This Year | $11.38 | N/A |
| Revenue Next Year | $6.11 | N/A |
| P/E Ratio | $20.50 | ★ N/A |
| Revenue Growth | ★ 7.20 | N/A |
| 52 Week Low | $178.21 | $30.77 |
| 52 Week High | $257.81 | $95.49 |
Technical Indicators
Market Signals| Indicator | RGA | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 47.88 | 25.28 |
| Support Level | $244.48 | $60.60 |
| Resistance Level | $251.00 | $71.83 |
| Average True Range (ATR) | 4.03 | 4.01 |
| MACD | -0.91 | -2.24 |
| Stochastic Oscillator | 17.36 | 10.13 |
Price Performance
Historical ComparisonAbout RGA Reinsurance Group of America Incorporated
Reinsurance Group of America Inc is an insurance holding company with operations in the United States, Latin America, Canada, Europe, Africa, Asia, and Australia. The core products and services include life reinsurance, living benefits reinsurance, group reinsurance, health reinsurance, financial solutions, facultative underwriting, and product development. The company's operations are divided into traditional and financial solution businesses.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.